Motif Labs (“Motif”), a Licensed Producer (LP) of cannabis products in Canada and leader in cannabinoid extraction, purification, and formulation, today announced it has received an amended license from Health Canada after successfully completing an intensive audit of its internal systems and processes. Through the new license, Motif receives approval from the government of Canada to manufacture and supply finished Cannabis 2.0 products directly to Canada’s provinces and territories including vaporizers, as well as topicals and tinctures. Now authorized to produce and white-label finished products for a growing number of popular brands, nationally, this marks a significant milestone for Motif and is testament not only to the talent within the organization, but their laser-focus on producing high-quality, consistent cannabinoid extractions for LP’s and third-party brands in Canada.

Following a thorough audit of our operations, processes and activities, the Motif Labs team and I are thrilled to receive this vote of confidence from Health Canada. This license opens up an additional revenue stream for Motif, and paves the way for us to bring a number of disruptive Cannabis 2.0 brands and products to market. With legal recreational cannabis sales on the rise in Canada, today’s announcement gives us the added flexibility to support this momentum, and to work with brands that are looking to diversify their product portfolio and increase their market share in the industry.

Mario Naric, Founder and CEO at Motif Labs

By registering with the appropriate provincial cannabis regulatory agencies, Motif is now able to list its brand partners’ product SKUs across Canada. Production of a variety of retail cannabis products offered by Motif’s existing portfolio of brand partners is already underway, with plans to begin shipping products across Canada’s provinces and territories in early 2021.